• Atonarp

  Participated · Series D · May 2021

  Atonarp develops molecular sensing and diagnostics products using proprietary spectroscopic technology to detect, analyze, and quantify molecular information. Its product suite includes the ATON-360™, an end-to-end platform designed to deliver lab-quality results using optical sensors. The company targets healthcare, pharmaceutical, and semiconductor industries with its devices and platforms. Atonarp operates in Japan, India, and the United States. Founded in 2010 and led by founder and CEO/CTO Prakash Murthy, the company recently appointed Shaun Holt as COO. Atonarp intends to use new funding to expand operations and expedite development and commercialization of its molecular diagnostics products. The company has raised $111M in funding to date. Atonarp is a Tokyo, Japan–based hi-tech molecular diagnostics company advancing a quantitative, miniaturized process mass spectrometer called AMS. The company also develops AI-based platforms combining mass spectrometry and optical spectroscopy for process monitoring and healthcare diagnostics. Atonarp aims to deliver pain-free point-of-care blood testing with lab-quality accuracy and real-time actionable data. It intends to use new funding to grow its balance sheet and support ongoing product prototyping and commercialization into the healthcare market. Led by CEO Prakash Murthy, the company has advanced its AMS and related platforms since early 2014. Since early 2014 Atonarp has raised more than $61M in three rounds of equity financing, including this Series C. Atonarp develops miniaturized Smart Spectrometer™ instruments for real-time molecular data analytics targeted at industrial gas process analytics in the energy, pharmaceutical, petrochemical and semiconductor industries. The company is commercializing its first generation of Smart Spectrometers and intends to use newly raised funds to support that commercialization. Atonarp was established in November 2009 and is led by CEO Prakash Murthy. The firm raised up to $16m in funding in the reported round. The product offering focuses on compact spectroscopic instruments and associated analytics for industrial customers. The company is headquartered in Tokyo and serves industrial process analytics markets. Atonarp is developing a Smart Spectrometer technology platform that combines state-of-the-art electronics and data processing algorithms to perform chemical composition analysis. The platform aims to deliver breakthroughs in cost, size, accuracy and maintenance-free operation without the need for carrier gases. Initial target markets for the company’s products are the oil & gas and healthcare industries, including non-invasive personal healthcare monitoring. Atonarp is currently sampling its Smart Spectrometer to leading manufacturers of oil & gas and healthcare instruments. The company plans to enter volume production early next year. The recent $8 million Series A financing will accelerate development and commercialization of the platform.

No current team members are available.